[HER2 expression in gastric cancer in Peru].
HER2 positivity is thought to be a negative prognostic factor in gastric cancer (GC), correlating with poor survival rates. Reported HER2-positivity rates in GC have varied widely (6-35%). Objective of this study is to determine rate of positivity and describe clinical and pathological characteristics of HER-2(+) GC. 100 GC tumour samples were centrally screened by immunohistochemistry and FISH. 9% of cases were positive. More positivity HER2 was found in advanced stages (III/IV) vs. early stages (I/II)(p=0.045) ; intestinal histology subtype vs diffuse/ mixed (p=0.045) and gastro-oesophageal junction cancer vs GC ( p=0.005).
Departamento Oncología Médica - Radioterapia Hospital Edgardo Rebagliati, Martins.
Brady
B
Beltran Gárate
Alejandro
A
Yabar Berrocal
D000368:Aged; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D010568:Peru; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics; D013274:Stomach Neoplasms / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human